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Abstract
Introduction: The role of nitric oxide synthase (NOS) in the pathophysiology of acute respiratory distress syndrome
(ARDS) is not well understood. Inducible NOS is upregulated during physiologic stress; however, if NOS substrate is
insufficient then NOS can uncouple and switch from NO generation to production of damaging peroxynitrites. We
hypothesized that NOS substrate levels are low in patients with severe sepsis and that low levels of the NOS
substrate citrulline would be associated with end organ damage including ARDS in severe sepsis.
Methods: Plasma citrulline, arginine and ornithine levels and nitrate/nitrite were measured at baseline in 135
patients with severe sepsis. ARDS was diagnosed by consensus definitions.
Results: Plasma citrulline levels were below normal in all patients (median 9.2 uM, IQR 5.2 - 14.4) and were
significantly lower in ARDS compared to the no ARDS group (6.0 (3.3 - 10.4) vs. 10.1 (6.2 - 16.6), P = 0.002). The rate
of ARDS was 50% in the lowest citrulline quartile compared to 15% in the highest citrulline quartile (P = 0.002). In
multivariable analyses, citrulline levels were associated with ARDS even after adjustment for covariates including
severity of illness.
Conclusions: In severe sepsis, levels of the NOS substrate citrulline are low and are associated with ARDS. Low
NOS substrate levels have been shown in other disease states to lead to NOS uncoupling and oxidative injury
suggesting a potential mechanism for the association between low citrulline and ARDS. Further studies are needed
to determine whether citrulline supplementation could prevent the development of ARDS in patients with severe
sepsis and to determine its role in NOS coupling and function.
Introduction
The role of nitric oxide synthases (NOS) and their product
nitric oxide (NO) in the pathophysiology of clinical acute
respiratory distress syndrome (ARDS) is still not well
understood. The signaling molecule NO can regulate a
number of processes important in the pathophysiology of
ARDS [1,2] including vascular tone, platelet aggregation,
leukocyte adhesion, and mitochondrial oxygen consump-
tion [3]. Production of NO is catalyzed by the three nitric
oxide synthases (NOS), and all three isoforms of NOS
(NOS-1, NOS-2 and NOS-3) are expressed in the lung.
The proximal substrate for NO synthesis by NOS is
L-arginine. L-arginine is synthesized primarily from the
urea cycle intermediate L-citrulline by argininosuccinate
synthase (ASS) and argininosuccinate lyase (ASL)
(Figure 1). Experiments in our laboratories have shown
that complexing of ASS and ASL with NOS in several
tissues results in substrate channeling of citrulline through
ASS and ASL to NOS to drive NO production [4]. In addi-
tion, we have recently observed that in human vascular
endothelial cells, extracellular citrulline and not arginine,
is the effective precursor of NO production. These find-
ings suggest that circulating levels of citrulline may be
more predictive of NOS function than arginine levels.
Circulating levels of L-citrulline are dependent on the
proximal urea cycle function of the gut and secondarily
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the liver [5] and low levels of citrulline and arginine have
been reported in adults [6,7] and children [8,9] with sep-
sis and other critical illness but have not been previously
reported in ARDS. We hypothesized that the physiologic
stress of sepsis would result in overall decreases in citrul-
line production to levels that could potentially lead to a
fall in NO production in the lung, and potentiate the
development of ARDS. We further hypothesized that
arginine levels would not be associated with ARDS
because of substrate channeling from citrulline to NO.
To test this hypothesis, we measured plasma levels of the
NO precursors citrulline and arginine, as well as the NO
products nitrate and nitrite in 135 patients with severe
sepsis enrolled in two randomized clinical trials of an
anti-tumor necrosis factor antibody. For comparison, we
also measured plasma levels of ornithine, an amino acid
that is not a direct substrate for NOS but is an intermedi-
ate in the urea cycle.
Materials and methods
Patients
Of the 141 patients enrolled in two phase II randomized
controlled studies of affinity-purified, anti-tumor necrosis
factor-a ovine fab fragments (CytoFab) 135 had baseline
plasma samples available for measurements and were
included in this analysis. Plasma was drawn from patients
as part of the clinical trial protocol at the time of enroll-
ment. After collection, plasma was centrifuged to remove
cells and the supernatant was stored in small aliquots at
-80C until thawed for amino acid analysis. For inclusion in
the clinical trials, documented or presumed infection, sys-
temic inflammatory response syndrome (SIRS), and pre-
sence of shock or dysfunction of two other organs were
required. Exclusion criteria have been previously published
[10,11]. The institutional review board or independent
ethics committee at each enrollment site approved the clini-
cal trials [10,11], as did the Vanderbilt Institutional Review
Board. Each participant or their surrogate provided
informed consent to participate in the study. Patients were
assessed for the presence of ARDS based on consensus defi-
nitions [12] on the day of clinical trial enrollment, which
was also the day of baseline plasma collection. Clinical data
including demographics, severity of illness scoring (Acute
Physiology and Chronic Health Evaluation, APACHE II)
[13], Brussels organ failure scores [14], laboratory values
and outcomes were obtained from the study databases.
Amino acid, nitrate and nitrite measurements
Plasma amino acid levels were measured by the Hitachi L-
8800I high performance amino acid analyzer (Pleasanton,
Figure 1 Schematic of the integration of nitric oxide production with the urea cycle. ARG1, arginase-1; CPSI, carbamyl phosphate synthase
inhibitor; NADPH, nicotinamide adenine dinucleotide phosphate; NAGS, N-acetylglutamate synthase; NO, nitric oxide; OTC, ornithine
transcarbamylase; TCA, tricarboxylic acid.
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CA, USA). Plasma total nitrate and nitrite (NOx) were
measured in duplicate by a Sievers 280I chemiluminescent
nitric oxide analyzer (GE, Boulder, CO, USA).
Statistical analysis
All statistical analysis was done using IBM SPSS Statistics
Version 19.0 for Macintosh. Amino acid levels and NOx
levels were not normally distributed and were compared
between groups using the Mann-Whitney U-test. Correla-
tions were assessed using Spearman rank correlation coef-
ficients. Categorical variables were compared by chi
square analysis or Fisher’s exact test as appropriate. Multi-
variable logistic regression models were used to assess the
potential confounding effects of clinical variables on the
association of plasma citrulline levels with diagnosis of
ARDS. Potential confounders were included in the model
one at a time to assess the confounding effects of each
variable on the relationship of citrulline to ARDS [15]. In
logistic regression equations, citrulline was expressed as
odds ratio (OR) per 5 uM increment. A P-value less than
or equal to 0.05 was considered statistically significant.
Results
Patients
Patient characteristics are summarized in Table 1.
Patients with ARDS at enrollment were younger and
were more likely to be mechanically ventilated. They
were more likely to have coagulation failure and less
likely to have renal failure, but had a similar overall
severity of illness as measured by the APACHE II
score.
Amino acid levels and ARDS
The median plasma level of citrulline was very low at
9.2 uM (interquartile range (IQR) 5.2 to 14.4) compared
to a normal range of 40 ± 10 uM in healthy adults [16].
The median plasma level of arginine was also low at
22.7 uM (IQR 12.8 to 37.9) compared to a normal range
of 27 to 80 uM. The median level of ornithine was 22.7
uM (IQR 14.3 to 39.0), which was within the normal
range of 13 to 64 uM.
Amino acid levels are compared between patients with
and without ARDS in Table 2. Plasma levels of citrulline
were significantly lower in patients with ARDS at enroll-
ment compared to patients without ARDS (Figure 2a). By
contrast, plasma levels of ornithine and arginine did not
differ significantly between patients with and without
ARDS (Figures 2b and 2c). Among patients in the lowest
quartile of plasma citrulline level, the incidence of ARDS
was 50% compared to an incidence of 15% in the highest
quartile of plasma citrulline (P = 0.002 for trend across
quartiles) (Figure 3).
Table 1 Clinical characteristics of 135 patients with severe sepsis
Characteristic All patients1 ARDS
N = 44
No ARDS
N = 91
P-value2
Age, years 55 ± 16 49 ± 17 57 ± 16 0.011
Male, % 54 50 65 0.10
Caucasian, % 73 82 69 0.12
APACHE II score 24 ± 7 24 ± 7 24 ± 7 0.97
WBC, × 103 17.6 ± 12.0 17.0 ± 11.7 18.0 ± 12.1 0.66
Creatinine, mg/dL 2.4 ± 2.1 2.0 ± 2.3 2.6 ± 2.0 0.14
PaO2/FiO2 ratio 155 ± 88 102 ± 51 184 ± 91 < 0.001
Mechanically ventilated at enrollment, % 84 95 79 0.014
Liver failure, % 23 22 24 0.84
Renal failure, % 41 25 41 0.01
Coagulation failure, % 28 46 20 0.002
Mortality at 28 days, % 36 39 34 0.60
1Data are mean ± SD or percent of patients as indicated. 2P-value for comparison of patients with ARDS or without ARDS. APACHE II, Acute Physiology and
Chronic Health Evaluation; WBC, white blood cells; PaO2/FiO2, arterial to inspired oxygen ratio.
Table 2 Comparison of baseline plasma amino acid and NOx levels in patients with and without ARDS
Analyte ARDS1
n = 44
No ARDS
n = 91
P-value
Citrulline, uM 6.0 (3.3 - 10.4) 10.1 (6.2 - 16.6) 0.002
Arginine, uM 19.3 (9.6 - 34.5) 22.9 (14.7 - 40.0) 0.18
Ornithine, uM 23.0 (8.5 - 37.1) 22.3 (16.0 - 43.2) 0.22
NOx 53.8 (24.2 - 92.3) 49.8 (34.5 - 80.9) 0.89
1Data presented as median (IQR). ARDS, acute respiratory distress syndrome; NOx, total nitrate and nitrite.
Ware et al. Critical Care 2013, 17:R10
http://ccforum.com/content/17/1/R10
Page 3 of 8
Amino acid levels and non-pulmonary organ failure
Amino acid levels were not different between patients with
and without renal failure (median 9.4, IQR 5.0 to 12.7 vs.
8.3 uM, IQR 5.2 to 15.1; P = 0.68). There were also no
differences in amino acid levels between patients with and
without cardiovascular failure (shock) and liver failure as
defined by the Brussels organ failure scoring system. How-
ever, there was a trend towards lower citrulline levels in
patients with coagulation failure (thrombocytopenia) (P =
0.060). Plasma NOx levels were significantly higher in
patients with renal failure (median 70.6 Um, IQR 41.4 to
101.1 vs. 40.6 uM, IQR 22.6 to 72.1; P < 0.001), and plasma
NOx levels were significantly associated with serum creati-
nine measurements (r = 0.48; P < 0.001).
Multivariable analysis
The association of plasma citrulline levels with ARDS
was assessed after adjustment for potential confounding
variables in multivariable analyses. The unadjusted OR
for ARDS associated with a 5 uM decrease in plasma
citrulline level was 1.50 (95% CI, 1.14, 1.98; P = 0.004).
Adjustment for other covariates including age, gender,
ethnicity, APACHE II level, and presence of shock did
not alter this relationship (Table 3).
Figure 2 Box plot summary of plasma levels of citrulline (panel A), arginine (panel B) and ornithine (panel C) in 135 patients with
severe sepsis. Citrulline levels were significantly lower in patients with acute respiratory distress syndrome (ARDS) compared to patients without
ARDS. Horizontal line represents median, box encompasses 25th to75th percentile, error bars encompass 10th to 90th percentile. *P = 0.002.
Figure 3 Incidence of acute respiratory distress syndrome
(ARDS) by quartile of plasma citrulline level. Plasma citrulline
levels in each quartile were: 1st quartile 0 to 5.12 uM, 2nd quartile
5.16 to 8.56 uM, 3rd quartile 9.15 to 14.18 uM, 4th quartile 14.35 to
50.07 uM. Patients with the lowest plasma citrulline level
(1st quartile) had the highest percentage of patients with ARDS.
P = 0.002 for trend across quartiles.
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Clinical outcomes
In patients with ARDS, amino acid levels were not sig-
nificantly associated with mortality (Table 4) or ventila-
tor-free days (not shown).
Discussion
We hypothesized that the physiologic stress of sepsis
would result in decreased citrulline production and that
lower circulating levels of citrulline would be associated
with the occurrence of ARDS. We observed markedly
low plasma levels of citrulline in all patients with severe
sepsis, and a significant association between lower
citrulline levels and the occurrence of ARDS in sepsis.
Furthermore, lower levels of plasma citrulline were inde-
pendently associated with a diagnosis of ARDS, even
when controlling for measures of severity of illness. The
finding of a strong association between low citrulline
levels and presence of ARDS in sepsis patients suggests
that NOS substrate deficiency might play a role in the
pathogenesis of ARDS.
NOS are modular enzymes with both a reductase and
oxygenase domain (Figure 4). Coupling of electron
transfer between these domains leads to synthesis of
NO. When uncoupled, NOS preferentially catalyzes the
production of superoxide ion from reduction of molecu-
lar oxygen rather than NO [17]. Uncoupling of NOS
can be caused by oxidative stress [18], ischemia reperfu-
sion [19] and substrate deficiency [17]. In the current
study, substrate deficiency of citrulline would be
expected to lead to insufficient precursor in the ASS-
ASL-NOS system and uncoupling of NOS. This could
be an important mechanism contributing to the patho-
genesis of ARDS, since NOS uncoupling leads to an
increase in superoxide production and oxidant stress.
Chronic uncoupling of NOS is important in a variety of
disease processes including diabetes [3], hypertension
[3] and diastolic dysfunction [20].
Table 3 Multivariable analyses of association between plasma citrulline levels and ARDS in patients with severe sepsis
Variable Odds ratio per 5 uM decrease
in plasma citrulline (95% CI)
P-value
Unadjusted 1.50 (1.14, 1.98) 0.004
Adjusted for:
Age 1.43 (1.08, 1.89) 0.012
Gender 1.52 (1.14, 2.02) 0.004
Ethnicity 1.50 (1.14, 1.97) 0.004
APACHE II score 1.50 (1.14, 1.98) 0.004
Presence of shock 1.51 (1.14, 1.99) 0.004
ARDS, acute respiratory distress syndrome; APACHE II, Acute Physiology and Chronic Health Evaluation.
Table 4 Comparison of plasma amino acids and biomarkers of lung injury by 28-day mortality in patients with ARDS
(n = 44)
Analyte Lived1
n = 27
Died
n = 17
P-value
Citrulline 5.7 (3.6 - 9.8) 7.5 (1.9 - 12.6) 0.56
Arginine (uM) 19.9 (10.3 - 32.8) 18.8 (7.8 - 37.8) 0.88
Ornithine (uM) 23.2 (11.5 - 34.9) 20.6 (5.3 - 41.0) 0.74
NOx 34.8 (23.4 - 72.7) 60 (42.2 - 124.2) 0.06
1Data as presented as median (IQR). ARDS, acute respiratory distress syndrome; NOx, total nitrate and nitrite.
Figure 4 Schematic of a nitric oxide synthase (NOS) dimer with
both the oxygenase and reductase domains shown. Coupling of
electron transfer between these domains leads to synthesis of nitric
oxide (NO). When uncoupled, NOS preferentially catalyzes the
production of superoxide ion from reduction of molecular oxygen
rather than NO. Uncoupling of NOS can be caused by oxidative
stress, ischemia reperfusion and substrate deficiency. Arg, arginine;
FMN, flavin mononucleotide binding domain; FAD, flavin adenine
dinucleotide binding domain; NADPH, nicotinamide adenine
dinucleotide phosphate.
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Although we hypothesized that substrate deficiency of
citrulline would lead to decreased NO production, it was
not possible to measure NO production prospectively in
the current study. We did measure plasma levels of NOx,
the stable byproducts of NO production. Plasma levels of
citrulline and arginine were not associated with plasma
levels of NOx, nor were NOx levels associated with the
presence of ARDS. Although one might predict that
substrate deficiency would lead to a fall in NO production,
and a resultant fall in plasma NOx levels, others have
reported that circulating NOx levels are strongly modu-
lated by renal excretion of NOx, which is impaired in the
setting of renal insufficiency [21]. Concordant with these
findings, plasma NOx levels in our study were strongly
and inversely associated with serum creatinine measure-
ments, and were significantly higher in patients with renal
failure. In a separate cohort, we previously reported that
low levels of urine nitric oxide species (NOx) are an inde-
pendent predictor of mortality in patients with ARDS [22].
Unfortunately, no urine was collected in the present study
for analysis of urine NOx species.
To our knowledge, there have not been any prior studies
of urea cycle products in clinical ARDS, although there
have been several small studies in patients with sepsis.
Freund et al. [23] measured plasma amino acid levels in
25 patients with sepsis and found that low arginine levels
were associated with mortality; citrulline was not mea-
sured in that study. Druml and colleagues [24] also
reported low levels of plasma arginine in nine patients
with sepsis. In 59 critically ill children, plasma arginine
and citrulline levels were lower in patients with sepsis or
trauma compared to patients with viral disease and were
inversely associated with severity of inflammation as indi-
cated by the plasma C-reactive protein concentration [8].
Several studies have examined arginine and citrulline flux
in critical illness and sepsis. Plasma arginine levels and
arginine production have been found to be low in six
adults with septic shock compared to healthy controls
[21]. In 13 adults with sepsis, plasma arginine and citrul-
line levels were found to be low compared to controls, as
was the rate of citrulline flux [9]. Luiking et al. reported
similar findings of very low citrulline levels and low rates
of citrulline production in 10 patients with septic shock
and concluded that the fall in citrulline production was
driven by diminished de novo arginine and NO production
[7]. The current findings of low plasma levels of citrulline
and arginine in patients with severe sepsis are concordant
with these prior studies and provide additional new infor-
mation regarding the independent association of low
citrulline levels with development of ARDS in severe sep-
sis. In light of our recent report of ASS-ASL-NOS com-
plex formation and substrate channeling [4], citrulline
substrate availability is likely to be the primary external
factor affecting the ability of cells to maintain coupling of
NOS. Furthermore, citrulline enters the cell with relatively
little competition through neutral amino transport, while
arginine uses dibasic amino acid transport, and we detect
very little free arginine inside cells [25], findings that also
favor a primary role for citrulline availability in regulation
of NOS coupling.
Although it was not possible in this observational
study to determine the mechanisms that lead to low
citrulline levels in this critically ill cohort of patients
with severe sepsis, there are several possible mechan-
isms. Decreased nutritional intake is common in the
early stages of critical illness and could be a potential
mechanism leading to low substrate levels for citrulline
production. However, levels of ornithine and other
amino acids such as glycine and glutamine (data not
shown) were in the normal range, suggesting that
decreased nutritional intake is not the primary driver of
low citrulline and arginine levels in this study. Gut
enterocytes are an important source of citrulline pro-
duction that can be injured in critical illness. Indeed,
plasma citrulline levels have been proposed as a func-
tional indicator of small bowel enterocyte mass [26].
Thus, decreased enterocyte production is one potential
mechanism of low citrulline levels that may be relevant
in both sepsis and ARDS [27]. Although we did not
measure arginase activity in this study, increases in argi-
nase activity could also contribute to low circulating
citrulline levels since arginase and NOS compete for
arginine substrate. Arginase activity can increase in the
setting of sepsis and oxidative stress [28]. However, in a
shock model in rats, arginase in the lung was downregu-
lated, arguing against arginase upregulation in the lung
as a major determinant of local levels in the lung [29].
The association of low levels of plasma citrulline with
development of ARDS in patients with severe sepsis
might have implications for the prevention and/or treat-
ment of ARDS. Citrulline repletion is already being
tested in other clinical settings that are associated with
NOS substrate deficiency. In pulmonary hypertension
after congenital heart surgery, low levels of citrulline
have been shown to predict reduced NO production
and poor clinical outcomes [30]. In an early phase clini-
cal trial, intravenous citrulline supplementation was safe
and well tolerated in children undergoing congenital
heart surgery with cardiopulmonary bypass, and led to
increases in plasma NOx and arginine levels as well as a
reduction in post-operative pulmonary hypertension,
without any evidence of systemic changes in blood pres-
sure [31]. A larger clinical trial in children undergoing
cardiac surgery with cardiopulmonary bypass is ongoing.
This study has several strengths. A major strength is
the size of the study with 135 critically ill patients,
which to our knowledge is the largest study of NOS
substrate levels in critical illness to date. Because of the
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large size of the study we were able to test the associa-
tion of NOS substrate levels with other organ failures
and clinical outcomes in addition to ARDS. This study
also has limitations. First, although the association
between low levels of citrulline and ARDS was robust, it
provides only indirect evidence that substrate deficiency
leading to NOS uncoupling is important in the patho-
physiology of ARDS; we were not able to directly mea-
sure either NO or superoxide production in this study,
and the plasma NOx measures appeared to be modu-
lated by renal failure. In addition, ARDS could be a
cause rather than a consequence of low substrate levels.
A second limitation is that we did not measure tetrahy-
drobiopterin (BH4) levels. BH4 is a NOS cofactor that is
normally bound to the NOS oxygenase domain [19].
BH4 levels can be reduced in the setting of oxidative
stress [18] and ischemia reperfusion [19]. However, like
NOx, circulating BH4 levels are affected by renal failure
[32], and it is not clear that circulating levels are a good
indicator of potential BH4 effects on NOS. A final lim-
itation is that the measurements were made at only a
single point in time. In future studies it would be help-
ful to determine changes in citrulline and arginine levels
over time in association with development of ARDS.
Conclusions
In summary, plasma citrulline levels are low in patients
with severe sepsis and low levels are associated with the
presence of ARDS. Further studies are needed to deter-
mine whether citrulline supplementation could prevent
the development of ARDS in patients with severe sepsis.
Key messages
• Circulating levels of citrulline, the primary substrate
for NOS, are low in patients with severe sepsis.
• Low levels of circulating citrulline are associated
with development of ARDS in patients with severe
sepsis.
• Prospective studies are needed to determine
whether citrulline supplementation could prevent
the development of ARDS in patients with severe
sepsis.
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